IMVT NASDAQ
Immunovant, Inc.
1W: +1.0%
1M: -14.9%
3M: -12.9%
YTD: +29.8%
1Y: +105.8%
3Y: -14.9%
5Y: +288.7%
$33.62
-0.03 (-0.09%)
Weekly Expected Move ±4.8%
$30
$32
$34
$35
$37
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (63)
Immunovant, Inc. (NASDAQ:IMVT) Stock Rated “Moderate Buy” by Sell-Side Brokerages
IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down
Roivant slips as Immunovant faces trial setback for cutaneous lupus therapy
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
1,181,452 Shares in Immunovant, Inc. $IMVT Purchased by Bank of America Corp DE
Engineers Gate Manager LP Raises Stock Holdings in Immunovant, Inc. $IMVT
Algert Global LLC Raises Position in Immunovant, Inc. $IMVT
Immunovant (NASDAQ:IMVT) Sets New 12-Month High – Still a Buy?
Assenagon Asset Management S.A. Has $639,000 Holdings in Immunovant, Inc. $IMVT
Immunovant (IMVT) Q1 2027 Earnings Call Transcript
Immunovant, Inc. Q1 2027 Earnings Call Summary
Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress
Immunovant, Inc. (NASDAQ:IMVT) Receives $39.70 Consensus Target Price from Brokerages
Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?
Immunovant Stock Gains 12.4% in a Month: What's Driving It?
Truist Lifts PT on Immunovant, Inc. (IMVT) But Maintains a Hold Rating
These Analysts Increase Their Forecasts On Immunovant After Q4 Results
IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data
Immunovant Stock Surges Despite Disappointing Earnings Miss
12 Health Care Stocks Moving In Wednesday's Intraday Session
TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Moving Higher On Wednesday
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Earnings Scheduled For May 20, 2026
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026
Here are the major earnings before the open Wednesday
Immunovant Q4 2026 Earnings Preview
Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
Immunovant (NASDAQ:IMVT) CTO Sells $81,573.48 in Stock
Immunovant (NASDAQ:IMVT) CFO Sells $763,011.20 in Stock
Insider Selling: Immunovant (NASDAQ:IMVT) COO Sells $216,567.26 in Stock
Immunovant (NASDAQ:IMVT) CTO Sells $251,577.56 in Stock
Insider Selling: Immunovant (NASDAQ:IMVT) Insider Sells $128,246.95 in Stock
Immunovant, Inc. (NASDAQ:IMVT) Receives Consensus Recommendation of “Hold” from Brokerages
IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints
Eric Venker Sells 14,229 Shares of Immunovant (NASDAQ:IMVT) Stock
Aberdeen Group plc Increases Stake in Immunovant, Inc. $IMVT
Alto Neuroscience, Immunovant And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Immunovant falls on late-stage trial setback for TED therapy
Why Globalstar Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
Immunovant (NASDAQ:IMVT) Insider Sells $71,838.69 in Stock
Immunovant, Inc. $IMVT is Alpine Global Management LLC’s 3rd Largest Position
Analysts Set Immunovant, Inc. (NASDAQ:IMVT) PT at $32.50
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?
Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish
Immunovant Stock Surges 17% in 3 Months: What's Driving It?
Citigroup Inc. Sells 75,860 Shares of Immunovant, Inc. $IMVT
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)
Immunovant (NASDAQ:IMVT) Hits New 12-Month High After Strong Earnings
IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus
Immunovant, Inc. (IMVT) Q3 2026 Earnings Call Transcript
Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025
Wall Street Analysts Predict a 55.04% Upside in Immunovant (IMVT): Here's What You Should Know
Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
SG Americas Securities LLC Has $1.01 Million Stock Holdings in Immunovant, Inc. $IMVT
Analyzing Northwest Biotherapeutics (OTCMKTS:NWBO) & Immunovant (NASDAQ:IMVT)
How Much Upside is Left in Immunovant (IMVT)? Wall Street Analysts Think 47.39%
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million?
Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement
Immunovant Announces Pricing of $550 Million Common Stock Financing
55,524 Shares in Immunovant, Inc. $IMVT Purchased by Capital Fund Management S.A.